X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A2B530 consists of an activator that targets carcinoembryonic antigen (CEA) and a blocker that targets HLA-A*02, which is intended to provide selective killing of tumor tissues. It is being investigated for colorectal, pancreatic and non-small cell lung cancers.
Lead Product(s): A2B530
Therapeutic Area: Oncology Product Name: A2B530
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
A2 Bio’s candidate has been validated by robust pre-clinical in vitro and in vivo studies. Tmod™ CEA-targeted CAR T cells, A2B530, can seek CEA expressing tumors, then activate, proliferate and eliminate the tumors while protecting against activity on normal tissues.
Lead Product(s): A2B530
Therapeutic Area: Oncology Product Name: A2B530
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
A2B530 (Tmod CEA CAR T cell Therapy), selectively kill tumor cells while sparing normal cells, demonstrating the potential providing a radical new way to safely and effectively treat solid tumor cancers.
Lead Product(s): Tmod CEA CAR T Cell Therapy
Therapeutic Area: Oncology Product Name: A2B530
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
A2 will continue research and preclinical development of its undisclosed Tmod cell therapy candidate (its third candidate therapy), with the parties to co-fund A2’s clinical development and allogeneic manufacturing activities through Phase 1.
Lead Product(s): Tmod-based cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 23, 2020
Details:
Proceeds will fund the advancement of its Tmod (T-cell module) platform and the clinical development and in-house manufacturing of its three near-term product candidates.
Lead Product(s): Tmod-engineered T cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The Column Group
Deal Size: $71.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
